• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.

作者信息

Resch B, Gusenleitner W, Müller W D, Haas J

机构信息

Division of Neonatology, Department of Paediatrics, Medical University Graz, Auenbruggerplatz 30, 8036, Graz, Austria.

出版信息

Eur J Clin Microbiol Infect Dis. 2006 Feb;25(2):120-2. doi: 10.1007/s10096-005-0082-y.

DOI:10.1007/s10096-005-0082-y
PMID:16491302
Abstract
摘要

相似文献

1
Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.对29至32周龄早产儿呼吸道合胞病毒相关住院情况及帕利珠单抗使用情况的观察性研究。
Eur J Clin Microbiol Infect Dis. 2006 Feb;25(2):120-2. doi: 10.1007/s10096-005-0082-y.
2
Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.在日本对高危婴儿引入帕利珠单抗后呼吸道合胞病毒感染导致的儿科病房住院情况调查。
Pediatr Int. 2011 Jun;53(3):368-73. doi: 10.1111/j.1442-200X.2010.03249.x.
3
Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.限制使用帕利珠单抗的建议及其对胎龄 > 29 周出生婴儿 RSV 住院率的影响：一项意大利多中心研究。
Am J Perinatol. 2019 Jul;36(S 02):S77-S82. doi: 10.1055/s-0039-1691771. Epub 2019 Jun 25.
4
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.1998年至2002年帕利珠单抗预防呼吸道合胞病毒疾病：四年使用帕利珠单抗的结果
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54. doi: 10.1097/01.inf.0000053885.34703.84.
5
Prevention of respiratory syncytial virus infection with palivizumab.使用帕利珠单抗预防呼吸道合胞病毒感染。
Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8.
6
[Guidelines for respiratory syncytial virus prophylaxis. An update].[呼吸道合胞病毒预防指南。更新版]
An Esp Pediatr. 2002 Apr;56(4):334-6.
7
The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .帕利珠单抗预防胎龄 32-35 周早产儿呼吸道合胞病毒感染的成本效果分析：基于加拿大的研究
Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234. Epub 2008 Oct 16.
8
Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.在家中使用帕利珠单抗的治疗效果改善：2000 - 2004年帕利珠单抗疗效登记研究结果
Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4.
9
Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.基于奥地利长期的流行病学数据，评估高危儿童呼吸道合胞病毒感染使用帕利珠单抗的成本效益。
Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.
10
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.帕利珠单抗预防对降低早产儿呼吸道合胞病毒住院率的影响。
Pediatr Infect Dis J. 2003 Sep;22(9):823-7. doi: 10.1097/01.inf.0000086403.50417.7c.

引用本文的文献

1
Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.帕利珠单抗预防呼吸道合胞病毒引起的严重下呼吸道感染的有效性和安全性：系统评价。
Am J Perinatol. 2024 May;41(S 01):e1107-e1115. doi: 10.1055/a-1990-2633. Epub 2022 Nov 30.
2
Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.儿童呼吸道合胞病毒感染预防与治疗的过去、现在及未来方法
Infect Dis Ther. 2018 Mar;7(1):87-120. doi: 10.1007/s40121-018-0188-z. Epub 2018 Feb 22.
3
Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.

本文引用的文献

1
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.帕利珠单抗预防2000 - 2001年呼吸道合胞病毒疾病：帕利珠单抗疗效登记研究结果
Pediatr Pulmonol. 2003 Jun;35(6):484-9. doi: 10.1002/ppul.10288.
2
Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.德国早产儿呼吸道合胞病毒相关住院的发病率及危险因素
Eur J Pediatr. 2003 Apr;162(4):230-6. doi: 10.1007/s00431-002-1105-7. Epub 2003 Mar 1.
3
Respiratory syncytial virus prophylaxis--the story so far.
使用帕利珠单抗预防风险评分工具评估孕29至32周早产儿呼吸道合胞病毒相关住院情况
Eur J Clin Microbiol Infect Dis. 2017 Jun;36(6):1057-1062. doi: 10.1007/s10096-016-2891-6. Epub 2017 Jan 11.
4
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.确定无慢性肺病或先天性心脏病的早产儿中严重呼吸道合胞病毒感染的风险及相关发病率和死亡率。
Infect Dis Ther. 2016 Dec;5(4):417-452. doi: 10.1007/s40121-016-0130-1. Epub 2016 Sep 14.
5
Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.意大利血流动力学显著的先天性心脏病患儿生命最初两年呼吸系统疾病的发病率：一项回顾性研究
Pediatr Cardiol. 2016 Dec;37(8):1581-1589. doi: 10.1007/s00246-016-1473-9. Epub 2016 Aug 29.
6
Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.健康早产儿呼吸道合胞病毒住院情况：系统评价
Pediatr Infect Dis J. 2016 Jul;35(7):e229-38. doi: 10.1097/INF.0000000000001163.
7
Prematurity and the burden of influenza and respiratory syncytial virus disease.早产以及流感和呼吸道合胞病毒疾病的负担。
World J Pediatr. 2016 Feb;12(1):8-18. doi: 10.1007/s12519-015-0055-x. Epub 2015 Nov 19.
8
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.帕利珠单抗预防高危儿童呼吸道合胞病毒住院的有效性：一项真实世界视角的研究。
Int J Pediatr. 2014;2014:571609. doi: 10.1155/2014/571609. Epub 2014 Dec 4.
9
RSV infection among children born moderately preterm in a community-based cohort.基于社区队列研究的中度早产儿童呼吸道合胞病毒感染情况
Eur J Pediatr. 2015 Apr;174(4):435-42. doi: 10.1007/s00431-014-2415-2. Epub 2014 Sep 6.
10
Prospective evaluation of clinical scoring systems in infants with bronchiolitis admitted to the intensive care unit.毛细支气管炎患儿入住重症监护病房的临床评分系统的前瞻性评估。
Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2667-72. doi: 10.1007/s10096-012-1612-z. Epub 2012 Apr 21.
呼吸道合胞病毒预防——迄今为止的情况。
Respir Med. 2002 Apr;96 Suppl B:S15-24. doi: 10.1016/s0954-6111(02)90066-1.
4
Epidemiology of respiratory syncytial virus infection in Southern Austria.奥地利南部呼吸道合胞病毒感染的流行病学
Pediatr Infect Dis J. 2000 Jun;19(6):587-8. doi: 10.1097/00006454-200006000-00030.
5
Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada.患有基础肺部疾病患者呼吸道合胞病毒感染的发病率差异：对加拿大儿科感染性疾病调查员协作网络呼吸道合胞病毒数据库的综述。加拿大儿科感染性疾病调查员协作网络
Pediatr Infect Dis J. 1999 Oct;18(10):866-9. doi: 10.1097/00006454-199910000-00006.
6
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.呼吸道合胞病毒感染的预防：帕利珠单抗的使用指征及呼吸道合胞病毒免疫球蛋白静脉注射剂使用的最新情况。美国儿科学会传染病委员会及胎儿与新生儿委员会
Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211.
7
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.呼吸道合胞病毒人源化单克隆抗体在早产儿和支气管肺发育不良婴儿中的安全性和药代动力学。MEDI - 493研究组
Pediatr Infect Dis J. 1998 Sep;17(9):787-91. doi: 10.1097/00006454-199809000-00007.
8
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.对高危婴幼儿预防性给予呼吸道合胞病毒免疫球蛋白。呼吸道合胞病毒免疫球蛋白研究组。
N Engl J Med. 1993 Nov 18;329(21):1524-30. doi: 10.1056/NEJM199311183292102.
9
Rehospitalization in the first year of life for high-risk survivors.高危幸存者在生命的第一年再次住院情况。
Pediatrics. 1980 Dec;66(6):991-9.